Search

Your search keyword '"Kornblit, Brian"' showing total 316 results
Start Over Author "Kornblit, Brian"
316 results on '"Kornblit, Brian"'

1. Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Author

Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Reinhardt, H. Christian, Afanasyeva, Ksenia, Avenoso, Daniele, Holderried, Tobias A. W., Kornblit, Brian Thomas, Gavriilaki, Eleni, Martinez, Carmen, Chiusolo, Patrizia, Mico, Maria Caterina, Daguenet, Elisabeth, Wichert, Stina, Ozdogu, Hakan, Piekarska, Agnieszka, Kinsella, Francesca, Basak, Grzegorz W., Schoemans, Hélène, Koenecke, Christian, Moiseev, Ivan, and Peric, Zinaida

Published
2025
Full Text
View/download PDF

2. ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Author

Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Reinhardt, H. Christian, Afanasyeva, Ksenia, Avenoso, Daniele, Holderried, Tobias A. W., Kornblit, Brian Thomas, Gavriilaki, Eleni, Martinez, Carmen, Chiusolo, Patrizia, Mico, Maria Caterina, Daguenet, Elisabeth, Wichert, Stina, Ozdogu, Hakan, Piekarska, Agnieszka, Kinsella, Francesca, Basak, Grzegorz W., Schoemans, Hélène, Koenecke, Christian, Moiseev, Ivan, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

9. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

10. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

Author

Sandmaier, Brenda M, Kornblit, Brian, Storer, Barry E, Olesen, Gitte, Maris, Michael B, Langston, Amelia A, Gutman, Jonathan A, Petersen, Soeren L, Chauncey, Thomas R, Bethge, Wolfgang A, Pulsipher, Michael A, Woolfrey, Ann E, Mielcarek, Marco, Martin, Paul J, Appelbaum, Fred R, Flowers, Mary E D, Maloney, David G, and Storb, Rainer

Published
2019
Full Text
View/download PDF

12. ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Boreland, William, additional, Lemaitre, Jessica, additional, Afanasyeva, Ksenia, additional, Kornblit, Brian, additional, Jurado, Manuel, additional, Martinez, Carmen, additional, Natale, Annalisa, additional, Pérez-Simón, Jose Antonio, additional, Brunello, Lucia, additional, Avenoso, Daniele, additional, Klein, Stefan, additional, Ozkurt, Zubeyde Nur, additional, Herrera, Concha, additional, Wichert, Stina, additional, Chiusolo, Patrizia, additional, Gavriilaki, Eleni, additional, Basak, Grzegorz W., additional, Schoemans, Hélène, additional, Koenecke, Christian, additional, Moiseev, Ivan, additional, and Peric, Zinaida, additional

Published
2023
Full Text
View/download PDF

15. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT

Author

Moiseev, Ivan S., Tsvetkova, Tatyana, Aljurf, Mahmoud, Alnounou, Randa M, Bogardt, Janet, Chalandon, Yves, Drokov, Mikhail Yu., Dvirnyk, Valentina, Faraci, Maura, Friis, Lone Smidstrup, Giglio, Fabio, Greinix, Hildegard T., Kornblit, Brian Thomas, Koelper, Christiane, Koenecke, Christian, Lewandowski, Krzysztof, Niederwieser, Dietger, Passweg, Jakob R., Peczynski, Christophe, Penack, Olaf, Peric, Zinaida, Piekarska, Agnieszka, Ronchi, Paola Erminia, Rovo, Alicia, Rzepecki, Piotr, Scuderi, Francesca, Sigrist, Daniel, Siitonen, Sanna M., Stoelzel, Friedrich, Sulek, Kazimierz, Tsakiris, Dimitrios A., Wilkowojska, Urszula, Duarte, Rafael F, Ruutu, Tapani, and Basak, Grzegorz W

Published
2019
Full Text
View/download PDF

16. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

Author

Minculescu, Lia, primary, Reekie, Joanne, additional, Petersen, Soeren Lykke, additional, Kornblit, Brian Thomas, additional, Schjoedt, Ida, additional, Andersen, Niels Smedegaard, additional, Andersen, Lisbeth Pernille, additional, Fischer-Nielsen, Anne, additional, Haastrup, Eva Kannik, additional, Friis, Lone Smidstrup, additional, and Sengelov, Henrik, additional

Published
2023
Full Text
View/download PDF

17. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.

Author

Minculescu, Lia, Reekie, Joanne, Petersen, Soeren Lykke, Kornblit, Brian Thomas, Schjoedt, Ida, Andersen, Niels Smedegaard, Andersen, Lisbeth Pernille, Fischer-Nielsen, Anne, Haastrup, Eva Kannik, Friis, Lone Smidstrup, and Sengelov, Henrik

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, MYELODYSPLASTIC syndromes, OVERALL survival, LYMPHOCYTES
Abstract

Introduction: Donor lymphocyte infusion (DLI) is used to induce remission in patients who relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the hypomethylating agent Azacitidine has been used together with DLI for a synergistic graft-versus-leukemia (GVL) effect. Here, we report results of DLI/Azacitidine treatment from a retrospective single-center study. Methods: Fifty AML/MDS patients treated for relapse after allo-HSCT between 2001 and 2020 with DLI at the Department of Hematology, at Rigshospitalet, Copenhagen University Hospital were included for analyses. A subgroup of patients who obtained complete remission (CR) after reinduction chemotherapy, received DLI in combination with low-dose (32 mg/m2) Azacitidine. Results: Overall survival in all patients after DLI treatment was 59% at 2 years and 20% at 5 years. Relapse-free survival in patients in CR prior to DLI was 32% after 2 years and 7% after 5 years. In the DLI + low-dose-Azacitidine group, 5-year relapse-free survival was 40%. Conclusion: DLI remains an effective treatment in post-transplant relapse leaving one-fifth of patients' long-term survivors. Our results support the concomitant use of low-dose Azacitidine in the future use of DLI in order to enhance the GVL effect of donor lymphocytes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation

Author

Schierbeck, Frederikke, Mortensen, Jann, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, Sengeløv, Henrik, Schierbeck, Frederikke, Mortensen, Jann, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, and Sengeløv, Henrik

Abstract

Objectives: The purpose of the study was to assess the validity of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and of pulmonary comorbidity prior to HCT in terms of predicting non-relapse mortality (NRM) and overall survival (OS). Methods: In this retrospective single-center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low-risk, intermediate-risk, and high-risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT-CI. Results: In univariate analysis, the HCT-CI and the PCS were associated with OS after transplantation when comparing patients in high-risk groups with patients in low-risk groups. Using the PCS, the hazard ratios (HRs) of the 2-year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p <.001) and 3.27 (p <.001), respectively, whereas the HRs using the HCT-CI were 1.83 (p <.001) and 2.57 (p =.002). The 2-year NRM incidence in the three risk-groups in the entire population was significant using both indexes. In the MAC group, the 2-year NRM was significant using the PCS (p =.003), but not using the HCT-CI (p =.23). Conclusions: Our study suggest that pulmonary function alone is a strong predictor of 2-year OS and NRM after HCT.

Published
2023

21. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020:A Danish population-based cohort study

Author

Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, Sengeløv, Henrik, Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, and Sengeløv, Henrik

Published
2023

22. ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party

Author

German Research Foundation, German Cancer Aid, Stiftung Charité, Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Afanasyeva, Ksenia, Kornblit, Brian, Jurado, Manuel, Martínez, Carmen, Natale, Annalisa, Pérez-Simón, José A., Brunello, Lucia, Avenoso, Daniele, Klein, Stefan, Ozkurt, Zubeyde Nur, Herrera, Concha, Wichert, Stina, Chiusolo, Patrizia, Gavriilaki, Eleni, Basak, Grzegorz W., Schoemans, Hélène, Koenecke, Christian, Moiseev, Ivan, Peric, Zinaida, German Research Foundation, German Cancer Aid, Stiftung Charité, Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Afanasyeva, Ksenia, Kornblit, Brian, Jurado, Manuel, Martínez, Carmen, Natale, Annalisa, Pérez-Simón, José A., Brunello, Lucia, Avenoso, Daniele, Klein, Stefan, Ozkurt, Zubeyde Nur, Herrera, Concha, Wichert, Stina, Chiusolo, Patrizia, Gavriilaki, Eleni, Basak, Grzegorz W., Schoemans, Hélène, Koenecke, Christian, Moiseev, Ivan, and Peric, Zinaida

Abstract

Introduction: Extracorporal Photophoresis (ECP) is in clinical use for steroid-refractory and steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results, ruxolitinib has become the new standard of care for SR-aGVHD. Our aim was to collect comparative data between ruxolitinib and ECP in SR-aGVHD in order to improve the evidence base for clinical decision making., Methods: We asked EBMT centers if they were willing to participate in this study by completing a data form (Med-C) with detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient., Results: 31 centers responded positively (14%) and we included all patients receiving alloSCT between 1/2017-7/2019 and treated with ECP or ruxolitinib for SR-aGVHD grades II-IV from these centers. We identified 53 and 40 patients with grades II-IV SR-aGVHD who were treated with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-aGVHD (steroid dependent vs. refractory). At day+90 after initiation of treatment for SR-aGVHD we found no statistically significant differences in overall response. The odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.13 (95% CI = [0.41; 3.22], p = 0.81). In line, we detected no statistically significant differences in overall survival, progression-free survival, non-relapse mortality and relapse incidence., Discussion: The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-aGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-aGVHD.

Published
2023

23. ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party

Author

Universidad de Sevilla. Departamento de Medicina, Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Afanasyeva, Ksenia, Kornblit, Brian, Pérez Simón, José Antonio, Peric, Zinaida, Universidad de Sevilla. Departamento de Medicina, Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Afanasyeva, Ksenia, Kornblit, Brian, Pérez Simón, José Antonio, and Peric, Zinaida

Abstract

Introduction: Extracorporal Photophoresis (ECP) is in clinical use for steroidrefractory and steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results, ruxolitinib has become the new standard of care for SRaGVHD. Our aim was to collect comparative data between ruxolitinib and ECP in SR-aGVHD in order to improve the evidence base for clinical decision making. Methods: We asked EBMT centers if they were willing to participate in this study by completing a data form (Med-C) with detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. Results: 31 centers responded positively (14%) and we included all patients receiving alloSCT between 1/2017-7/2019 and treated with ECP or ruxolitinib for SR-aGVHD grades II-IV from these centers. We identified 53 and 40 patients with grades II-IV SR-aGVHD who were treated with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-aGVHD (steroid dependent vs. refractory). At day+90 after initiation of treatment for SR-aGVHD we found no statistically significant differences in overall response. The odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.13 (95% CI = [0.41; 3.22], p = 0.81). In line, we detected no statistically significant differences in overall survival, progressionfree survival, non-relapse mortality and relapse incidence. Discussion: The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-aGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-aGVHD.

Published
2023

27. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study

Author

Gjærde, Lars K., primary, Jakobsen, Lasse H., additional, Juhl‐Christensen, Caroline, additional, Olesen, Gitte, additional, Petruskevicius, Irma, additional, Severinsen, Marianne T., additional, Marcher, Claus W., additional, Theilgaard‐Mönch, Kim, additional, Andersen, Niels S., additional, Friis, Lone S., additional, Kornblit, Brian, additional, Petersen, Søren L., additional, Schjødt, Ida, additional, and Sengeløv, Henrik, additional

Published
2022
Full Text
View/download PDF

28. Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation

Author

Gjærde, Lars Klingen, primary, Ostrowski, Sisse Rye, additional, Jørgensen, Niklas Rye, additional, Schierbeck, Frederikke, additional, Andersen, Niels Smedegaard, additional, Friis, Lone Smidstrup, additional, Kornblit, Brian, additional, Petersen, Søren Lykke, additional, Schjødt, Ida, additional, and Sengeløv, Henrik, additional

Published
2022
Full Text
View/download PDF

30. Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Author

Kornblit, Brian, Maloney, David G., Storb, Rainer, Storek, Jan, Hari, Parameswaran, Vucinic, Vladan, Maziarz, Richard T., Chauncey, Thomas R., Pulsipher, Michael A., Bruno, Benedetto, Petersen, Finn B., Bethge, Wolfgang A., Hübel, Kai, Bouvier, Michelle E., Fukuda, Takahiro, Storer, Barry E., and Sandmaier, Brenda M.

Published
2013
Full Text
View/download PDF

32. Possible Tacrolimus-Related Neuropsychiatric Symptoms:One Year After Allogeneic Hematopoietic Cell Transplantation: A Case Report

Author

Løhde, Linda W., Bentzon, Adrian, Kornblit, Brian T., Roos, Peter, Fink-Jensen, Anders, Løhde, Linda W., Bentzon, Adrian, Kornblit, Brian T., Roos, Peter, and Fink-Jensen, Anders

Abstract

Tacrolimus is a calcineurin inhibitor (CNI), an immunosuppressive agent used to prevent graft versus host disease following allogeneic hematopoietic cell transplantation (HCT). Side-effects of tacrolimus treatment include neuropsychiatric symptoms, for example, affective disturbances, psychosis, and akinetic mutism. The onset of side-effects is independent of tacrolimus blood concentration and can occur years after treatment initiation. To our knowledge, case-reports describing tacrolimus-induced neuropsychiatric symptoms following HCT are sparse. This article reports the case of a 60-year-old woman with T-cell prolymphocytic leukemia, who developed memory loss, affective disturbances, and delusions, 1-year after HCT, and tacrolimus treatmentinitiation. Upon hospital admission, she was motionless and mute, albeit easily roused. The routine physical examination was without pathological findings. Blood work and microbiological analyses of blood and cerebrospinal fluid were normal. The neuroimaging showed chronic structural changes without relation to the debut of neuropsychiatric symptoms. Tacrolimus was discontinued on suspicion of tacrolimus-induced neuropsychiatric symptoms. The patient recovered within 48 hours of discontinuation. She was switch to prednisone treatment, and there has been no reemergence of neuropsychiatric symptoms since.

Published
2022

33. Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults:a Danish population-based study

Author

Gjærde, Lars Klingen, Rank, Cecilie Utke, Andersen, Mette Klarskov, Jakobsen, Lasse Hjort, Sengeløv, Henrik, Olesen, Gitte, Kornblit, Brian, Marquart, Hanne, Friis, Lone Smidstrup, Petersen, Søren Lykke, Andersen, Niels Smedegaard, Nielsen, Ove Juul, Toft, Nina, Schjødt, Ida, Gjærde, Lars Klingen, Rank, Cecilie Utke, Andersen, Mette Klarskov, Jakobsen, Lasse Hjort, Sengeløv, Henrik, Olesen, Gitte, Kornblit, Brian, Marquart, Hanne, Friis, Lone Smidstrup, Petersen, Søren Lykke, Andersen, Niels Smedegaard, Nielsen, Ove Juul, Toft, Nina, and Schjødt, Ida

Abstract

We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000–2019. Patients had a median (min–max) age of 36 (18–74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27–66%) in year 2000 versus 77% (CI 59–88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00–1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93–1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87–0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93–1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.

Published
2022

40. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study.

Author

Gjærde, Lars K., Jakobsen, Lasse H., Juhl‐Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T., Marcher, Claus W., Theilgaard‐Mönch, Kim, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, and Sengeløv, Henrik

Subjects
ACUTE myeloid leukemia, CELL transplantation, COHORT analysis, HEMATOPOIETIC stem cell transplantation, CORD blood
Published
2023
Full Text
View/download PDF

41. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

Author

Minculescu, Lia, primary, Reekie, Joanne, additional, Petersen, Søren Lykke, additional, Kornblit, Brian Thomas, additional, Schjødt, Ida, additional, Andersen, Niels Smedegaard, additional, Andersen, Lisbeth Pernille, additional, Fischer-Nielsen, Anne, additional, Hastrup, Eva Kannik, additional, Friis, Lone Smidstrup, additional, and Sengeloev, Henrik, additional

Published
2021
Full Text
View/download PDF

42. Validation of Pre-Transplantation Plasma ST2 Levels As a Prognostic Marker of 1-Year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation

Author

Gjaerde, Lars Klingen, primary, Ostrowski, Sisse Rye, additional, Schierbeck, Frederikke, additional, Andersen, Niels Smedegaard, additional, Friis, Lone Smidstrup, additional, Kornblit, Brian Thomas, additional, Petersen, Søren Lykke, additional, Schjødt, Ida, additional, and Sengeloev, Henrik, additional

Published
2021
Full Text
View/download PDF

43. Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study

Author

Gjærde, Lars Klingen, primary, Rank, Cecilie Utke, additional, Andersen, Mette Klarskov, additional, Jakobsen, Lasse Hjort, additional, Sengeløv, Henrik, additional, Olesen, Gitte, additional, Kornblit, Brian, additional, Marquart, Hanne, additional, Friis, Lone Smidstrup, additional, Petersen, Søren Lykke, additional, Andersen, Niels Smedegaard, additional, Nielsen, Ove Juul, additional, Toft, Nina, additional, and Schjødt, Ida, additional

Published
2021
Full Text
View/download PDF

44. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

Author

Gjaerde, Lars Klingen, Ostrowski, Sisse Rye, Minculescu, Lia, Andersen, Niels Smedegaard, Friis, Lone Smidstrup, Kornblit, Brian, Petersen, Soren Lykke, Schjodt, Ida, Sengelov, Henrik, Gjaerde, Lars Klingen, Ostrowski, Sisse Rye, Minculescu, Lia, Andersen, Niels Smedegaard, Friis, Lone Smidstrup, Kornblit, Brian, Petersen, Soren Lykke, Schjodt, Ida, and Sengelov, Henrik

Abstract

Objectives Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD.Methods We studied 115 adults who underwent myeloablative allogeneic hematopoietic cell transplantation between July 2015 and August 2018. Vitamin E was measured by high-performance liquid chromatography in stored plasma samples obtained pre-transplantation at day -23 (+/- 15 days) and post-transplantation at day +28 (+/- 3 days).Results Pre-transplantation vitamin E levels were inversely associated with grade II-IV acute GvHD (hazard ratio 0.68 per 10 mu mol/L increase, 95% confidence interval [CI]: 0.47-0.98). The association remained after adjustment for known prognostic factors for acute GvHD. Patients with levels below the median had a cumulative incidence of grade II-IV acute GvHD of 46% (CI: 33-59%) versus 21% (CI: 10-32%) in patients with levels above the median. No clear association with non-relapse mortality, relapse, or chronic GvHD was found. Post-transplantation vitamin E levels (measured in 72 [63%] patients) were correlated with pre-transplantation levels (rho = .31) but were not associated with subsequent grade II-IV acute GvHD.Conclusions High pre-transplantation vitamin E levels were associated with less acute GvHD.

Published
2021

45. Functional immune reconstitution early after allogeneic haematopoietic cell transplantation: A comparison of pre‐ and post‐transplantation cytokine responses in stimulated whole blood

Author

Gjærde, Lars Klingen, primary, Brooks, Patrick Terrence, additional, Andersen, Niels Smedegaard, additional, Friis, Lone Smidstrup, additional, Kornblit, Brian, additional, Petersen, Søren Lykke, additional, Schjødt, Ida, additional, Nielsen, Susanne Dam, additional, Ostrowski, Sisse Rye, additional, and Sengeløv, Henrik, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results